Presentation of results for second quarter and first half of 2012
Presentation of results for second quarter and first half of 2012 will take place 09:00 (Norwegian time), Wednesday 29 August at Felix Conference Centre, Bryggetorget 3, Aker brygge in Oslo.
The presentation will be available on webcast with the following link:
After the presentation the webcast will be available on demand on the webpage www.diagenic.com under ‘Investor relations’.
Henrik Lund, CEO
Telephone: 47 90971219
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).
DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com